Analytical Data
-
Gene name
CYP1A1
- Application
-
Alternative Names
CYP1A1；ARO1；CYAR；CYP19；Aromatase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04798
-
Expression Region
1-512aa
-
AA Sequence
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIG HMLTLGKNPHLALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQG DDFKGRPDLYTFTLISNGQSMSFSPDSGPVWAARRRLAQNGLKSFSIASD PASSTSCYLEEHVSKEAEVLISTLQELMAGPGHFNPYRYVVVSVTNVICA ICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPILRYLPNPSLNA FKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTV IGRSRRPRLSDRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFY IPKGRCVFVNQWQINHDQKLWVNPSEFLPERFLTPDGAIDKVLSEKVIIF GMGKRKCIGETIARWEVFLFLAILLQRVEFSVPLGVKVDMTPIYGLTMKH ACCEHFQMQLRS
-
Molecular Weight
82 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP1A1, a member of the cytochrome P450 enzyme family, plays a crucial role in the metabolism of xenobiotics and endogenous compounds, particularly in the biotransformation of polycyclic aromatic hydrocarbons (PAHs) and other environmental toxins. This enzyme is primarily expressed in the liver and is regulated by various factors, including exposure to environmental pollutants, dietary components, and genetic polymorphisms. Research has demonstrated that CYP1A1 is involved in bioactivation pathways that can lead to the formation of reactive intermediates, contributing to toxicological effects and carcinogenesis. Understanding the structure and function of CYP1A1 through the use of recombinant protein technology has become imperative for elucidating its role in drug metabolism, toxicology, and disease susceptibility. The expression of recombinant CYP1A1 enables the detailed study of its enzymatic properties, substrate specificity, and interaction with various inhibitors, providing insights into its biochemical mechanisms. Moreover, investigating the implications of CYP1A1 activity in the context of individual variances in drug response and disease risk enhances the comprehension of personalized medicine and pharmacogenetics. Therefore, ongoing research into CYP1A1 recombinant protein not only contributes to basic scientific knowledge but also holds significant potential for applications in toxicology, pharmacology, and environmental health.
